Literature DB >> 16330668

Multipopulation analysis of polymorphisms in five mononucleotide repeats used to determine the microsatellite instability status of human tumors.

Olivier Buhard1, Francesca Cattaneo, Yick Fu Wong, So Fan Yim, Eitan Friedman, Jean-François Flejou, Alex Duval, Richard Hamelin.   

Abstract

PURPOSE: Human gastrointestinal tumors with inactivated DNA mismatch repair system (microsatellite instability [MSI] tumors) have distinct molecular and clinicopathologic profiles, and are associated with favorable prognosis. There is evidence suggesting that colorectal cancer patients with MSI tumors respond differently to adjuvant chemotherapy as compared with patients with non-MSI tumors. Finally, determination of the MSI status has clinical application for assisting in the diagnosis of suspected hereditary cases. It is thus becoming increasingly recognized that testing for MSI should be conducted systematically in all human cancers potentially of this type. We recently described a pentaplex polymerase chain reaction of five mononucleotide repeats to establish the MSI status of human tumors, and showed that this assay was 100% sensitive and specific. Moreover, these markers are quasimonomorphic in germline DNA of the white population (ie, individuals of Eurasian origin), and could be used for tumor MSI determination without the requirement for matching normal DNA in this group. PATIENTS AND METHODS: In this study, we analyzed a comparable panel of five mononucleotide markers in germline DNA from 1,206 individuals encompassing 55 different populations worldwide. Results With the exception of two Biaka Pygmies and one San individual for whom three markers showed variant alleles (three cases [0.2%]), the remaining 1,203 individuals showed no alleles of variant size (1,055 cases [87.5%]), or only one (122 cases [10.1%]) or two (26 cases [2.2%]) markers with variant alleles. All 60 MSI tumors investigated display instability in at least four of the five markers.
CONCLUSION: We demonstrated that tumor MSI status can be determined using the pentaplex reaction for all human populations without the need for matching normal DNA.

Entities:  

Mesh:

Year:  2005        PMID: 16330668     DOI: 10.1200/JCO.2005.02.7227

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  70 in total

1.  EPCAM germ line deletions as causes of Lynch syndrome in Spanish patients.

Authors:  Carla Guarinos; Adela Castillejo; Víctor-Manuel Barberá; Lucía Pérez-Carbonell; Ana-Beatriz Sánchez-Heras; Angel Segura; Carmen Guillén-Ponce; Ana Martínez-Cantó; María-Isabel Castillejo; Cecilia-Magdalena Egoavil; Rodrigo Jover; Artemio Payá; Cristina Alenda; José-Luís Soto
Journal:  J Mol Diagn       Date:  2010-09-23       Impact factor: 5.568

2.  Optimization of a pentaplex panel for MSI analysis without control DNA in a Brazilian population: correlation with ancestry markers.

Authors:  Nathália C Campanella; Gustavo N Berardinelli; Cristovam Scapulatempo-Neto; Danilo Viana; Edenir I Palmero; Rui Pereira; Rui M Reis
Journal:  Eur J Hum Genet       Date:  2013-11-06       Impact factor: 4.246

3.  Fusion tyrosine kinase NPM-ALK Deregulates MSH2 and suppresses DNA mismatch repair function novel insights into a potent oncoprotein.

Authors:  Leah C Young; Kathleen M Bone; Peng Wang; Fang Wu; Benjamin A Adam; Samar Hegazy; Pascal Gelebart; Jelena Holovati; Liang Li; Susan E Andrew; Raymond Lai
Journal:  Am J Pathol       Date:  2011-05-24       Impact factor: 4.307

Review 4.  Microsatellite instability testing and its role in the management of colorectal cancer.

Authors:  Hisato Kawakami; Aziz Zaanan; Frank A Sinicrope
Journal:  Curr Treat Options Oncol       Date:  2015-07

5.  Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis.

Authors:  Coralie Dorard; Aurélie de Thonel; Ada Collura; Laetitia Marisa; Magali Svrcek; Anaïs Lagrange; Gaetan Jego; Kristell Wanherdrick; Anne Laure Joly; Olivier Buhard; Jessica Gobbo; Virginie Penard-Lacronique; Habib Zouali; Emmanuel Tubacher; Sylvain Kirzin; Janick Selves; Gérard Milano; Marie-Christine Etienne-Grimaldi; Leila Bengrine-Lefèvre; Christophe Louvet; Christophe Tournigand; Jérémie H Lefèvre; Yann Parc; Emmanuel Tiret; Jean-François Fléjou; Marie-Pierre Gaub; Carmen Garrido; Alex Duval
Journal:  Nat Med       Date:  2011-09-25       Impact factor: 53.440

6.  Microsatellite instability in colorectal cancer: from molecular oncogenic mechanisms to clinical implications.

Authors:  Aziz Zaanan; Katy Meunier; Fatiha Sangar; Jean-François Fléjou; Françoise Praz
Journal:  Cell Oncol (Dordr)       Date:  2011-04-12       Impact factor: 6.730

7.  Analysis of microsatellite instability in medulloblastoma.

Authors:  Marta Viana-Pereira; Inês Almeida; Sónia Sousa; Bethânia Mahler-Araújo; Raquel Seruca; José Pimentel; Rui Manuel Reis
Journal:  Neuro Oncol       Date:  2009-01-29       Impact factor: 12.300

8.  An optimized pentaplex PCR for detecting DNA mismatch repair-deficient colorectal cancers.

Authors:  Ajay Goel; Takeshi Nagasaka; Richard Hamelin; C Richard Boland
Journal:  PLoS One       Date:  2010-02-24       Impact factor: 3.240

9.  Whole-exome sequencing of pancreatic neoplasms with acinar differentiation.

Authors:  Yuchen Jiao; Raluca Yonescu; G Johan A Offerhaus; David S Klimstra; Anirban Maitra; James R Eshleman; James G Herman; Weijie Poh; Lorraine Pelosof; Christopher L Wolfgang; Bert Vogelstein; Kenneth W Kinzler; Ralph H Hruban; Nickolas Papadopoulos; Laura D Wood
Journal:  J Pathol       Date:  2014-03       Impact factor: 7.996

10.  The TGFBR1*6A allele is not associated with susceptibility to colorectal cancer in a Spanish population: a case-control study.

Authors:  Adela Castillejo; Trinidad Mata-Balaguer; Paola Montenegro; Enrique Ochoa; Rafael Lázaro; Ana Martínez-Cantó; María-Isabel Castillejo; Carla Guarinos; Víctor-Manuel Barberá; Carmen Guillén-Ponce; Alfredo Carrato; José-Luís Soto
Journal:  BMC Cancer       Date:  2009-06-18       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.